EW-001 IIT study overall survival update
Filed with ASX · · 4 pages · English
Earlier from AdAlta
- 2 year survival milestone for EW-001 patient
- Oktopi AI collaboration for research efficiency
- Second BZDS1901 milestone paid
- Regulatory advisors appointed for BZDS1901
- $2.5m placement
Later from AdAlta
- BZDS1901 special access scheme launch in China
- Oribiotech deal validates AdAlta manufacturing strategy
- US FDA grants EW-001 pre-IND meeting
- China Representative Office opens
- EW-001 JDC milestone approvals
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta